Caldolor (Ibuprofen) Patent Expiration, LOE Window & CMS Spending

Caldolor (Ibuprofen) by Apotex: FDA Orange Book LOE 2032-03-16, 19 AB generics, $491K 2024 CMS Part D & Medicaid spend, and 7 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorApotex
FDA Application & PathwayN022348 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2032-03-16
Orange Book Patents (*PED Extensions)10 patents (0 *PED)
Active AB-Rated Generic Competitors19
2024 CMS Total Public Spend$491K
2024 Medicare Part D Spend$10K
2024 Medicaid Spend$481K
Reported Wholesale Price Change (CA SB 17)7 WAC filings (max 32.6% 2-yr change)